Navigation Links
Study shows immunohistochemistry is reliable screening tool for ALK rearrangement
Date:12/15/2012

DENVER Favorable results have led to crizotinib gaining approval for the treatment of advanced stage ALK-positive non-small cell lung cancer (NSCLC) in Japan, the United States, Canada, and several other countries in Europe and Asia. Now, the identification of an effective therapy for ALK-positive NSCLC places great emphasis on rapid, accurate, and cost-effective way to find patients with this subtype of lung cancer. A recent study published in the January 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes immunohistochemistry (IHC) is a reliable screening tool for identification of ALK rearrangement.

Fluorescence in situ hybridization (FISH) is the current standard method to detect ALK rearrangement. However, FISH is not readily available as a routine method of pathology practice in most laboratories because it is time consuming and requires advanced technical and professional expertise. In contrast, IHC is relatively inexpensive, faster, and is perfectly adapted for routine practice by academics and most community hospitals.

Researchers screened 377 stage I or II NSCLC cases, diagnosed between 1978 and 2002. Tissue microarray results were available on 377 cases by IHC and 273 cases by FISH. Eleven cases were positive or possibly positive by either IHC or FISH, and three cases were positive or possibly positive by both methods.

They found, "that all cases exhibiting ALK rearrangement demonstrated adenocarcinoma histology." Their results report a sensitivity of 100 percent and high specificity with the IHC with no false-negative results. While researchers acknowledge that further study involving a larger cohort is recommended, IHC is a valid screening test.

The lead author of this work is Dr. Chris M.J. Conklin. Co-authors include IASLC members Dr. Janessa Laskin, Dr. Kenneth Craddock, Cherry Have, Dr. Christian Couture and Dr. Diana Ionescu.


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Law that regulates shark fishery is too liberal: UBC study
3. New study will help protect vulnerable birds from impacts of climate change
4. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
5. BYU study: Using a gun in bear encounters doesnt make you safer
6. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
7. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
8. Crystal structure of archael chromatin clarified in new study
9. EU-funded study underlines importance of Congo Basin for global climate and biodiversity
10. University of Houston study shows BP oil spill hurt marshes, but recovery possible
11. Study demonstrates cells can acquire new functions through transcriptional regulatory network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
(Date:1/21/2017)... , Jan 20, 2017 Research and Markets ... Market 2017-2021" report to their offering. ... The global voice recognition biometrics market ... The report covers the present scenario and the ... To calculate the market size, the report considers the revenue generated ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... ... February 28, 2017 , ... ... antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with ... genetically engineered to express human antibodies. The partnership will use GigaGen technology to ...
(Date:2/28/2017)... 2017  ITL Limited ( ASX:ITD ), an ... partner that provides innovative products and solutions to ... announces its rebrand to ITL Health Group (ITL). ... of the Company,s unified global rebranding plan and ... corporate website, ITLHealthGroup.com . ITL,s new brand ...
(Date:2/28/2017)... and NEW YORK , February 28, ... Application accepted by the FDA for avelumab  Prognosis ... has metastasized   EMD ... Germany , in the US and Canada ... Food and Drug Administration (FDA) has accepted for Priority Review ...
(Date:2/27/2017)... A Europe-wide survey of institutes conducted by the Basel Declaration ... treat them with due care. The survey polled a total of ... indicates that there is a strong commitment among animal researchers across ... of the 3Rs (Refine, Reduce, Replace)  ... What are the 3Rs? Refine: ...
Breaking Biology Technology: